[go: up one dir, main page]

MX2011009704A - Anticuerpos humanizados con actividad anti-tumor. - Google Patents

Anticuerpos humanizados con actividad anti-tumor.

Info

Publication number
MX2011009704A
MX2011009704A MX2011009704A MX2011009704A MX2011009704A MX 2011009704 A MX2011009704 A MX 2011009704A MX 2011009704 A MX2011009704 A MX 2011009704A MX 2011009704 A MX2011009704 A MX 2011009704A MX 2011009704 A MX2011009704 A MX 2011009704A
Authority
MX
Mexico
Prior art keywords
humanized antibodies
human colon
humanised antibodies
tumour activity
tumor
Prior art date
Application number
MX2011009704A
Other languages
English (en)
Inventor
Philip Anthony Jennings
Anthony Gerard Doyle
Adam William Clarke
Norbert Alexander Kienzle
Matthew Pollard
Original Assignee
Cephalon Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2009901129A external-priority patent/AU2009901129A0/en
Application filed by Cephalon Australia Pty Ltd filed Critical Cephalon Australia Pty Ltd
Publication of MX2011009704A publication Critical patent/MX2011009704A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • G01N33/5752—
    • G01N33/57525—
    • G01N33/57535—
    • G01N33/57545—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona anticuerpos humanizados y dominios de enlace de los mismos con actividad anti-tumor. En particular los anticuerpos humanizados tienen enlace específico a y exterminio directo de células de tumor de colon humano y muestran potente actividad citotóxica inmuno-mediada contra células de cáncer de colon humano in vitro utilizando ensayos de citotoxicidad mediada por células dependientes de anticuerpos (ADCC) y citotoxicidad dependiente de complemento (CDC) e in vivo utilizando modelos de tumor de ratón.
MX2011009704A 2009-03-16 2010-03-16 Anticuerpos humanizados con actividad anti-tumor. MX2011009704A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16068209P 2009-03-16 2009-03-16
AU2009901129A AU2009901129A0 (en) 2009-03-16 Humanised antibodies with anti-tumour activity
US25851709P 2009-11-05 2009-11-05
PCT/AU2010/000298 WO2010105290A1 (en) 2009-03-16 2010-03-16 Humanised antibodies with anti-tumour activity

Publications (1)

Publication Number Publication Date
MX2011009704A true MX2011009704A (es) 2011-09-28

Family

ID=42739039

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011009704A MX2011009704A (es) 2009-03-16 2010-03-16 Anticuerpos humanizados con actividad anti-tumor.

Country Status (18)

Country Link
US (2) US8470320B2 (es)
EP (2) EP2408820A4 (es)
JP (1) JP5746134B2 (es)
KR (1) KR20110129935A (es)
CN (1) CN102395604B (es)
AU (1) AU2010225448B2 (es)
BR (1) BRPI1009460A2 (es)
CA (1) CA2769276A1 (es)
EA (1) EA024695B1 (es)
IL (1) IL214840A (es)
MA (1) MA33194B1 (es)
MX (1) MX2011009704A (es)
NZ (2) NZ600915A (es)
SG (1) SG173577A1 (es)
TN (1) TN2011000417A1 (es)
UA (1) UA108349C2 (es)
WO (1) WO2010105290A1 (es)
ZA (1) ZA201105875B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011054030A1 (en) 2009-11-05 2011-05-12 Cephalon Australia Pty Ltd Treatment of cancer involving mutated kras or braf genes
NZ756727A (en) 2011-10-28 2022-12-23 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
US9447193B2 (en) * 2013-03-24 2016-09-20 Development Center For Biotechnology Methods for suppressing cancer by inhibition of TMCC3
JP6286532B2 (ja) 2013-04-29 2018-02-28 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ３８抗体及び弱毒化インターフェロンアルファ−２ｂとの融合物
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
EP3212216A4 (en) 2014-10-29 2018-04-18 Teva Pharmaceuticals Australia Pty Ltd Interferon alpha2b variants
CN112710843B (zh) * 2020-12-16 2022-11-04 江苏伟禾生物科技有限公司 一种测定群体反应性抗体检测的板式免疫荧光试剂盒及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6042828A (en) 1992-09-07 2000-03-28 Kyowa Hakko Kogyo Co., Ltd. Humanized antibodies to ganglioside GM2
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6602684B1 (en) 1998-04-20 2003-08-05 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
DE69942636D1 (de) 1998-12-09 2010-09-09 Phyton Holdings Llc Verfahren zur herstellung von glycoprotein mit menschlichem glycosylierungsbild
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
ES2727425T3 (es) 2000-12-12 2019-10-16 Medimmune Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
US6881557B2 (en) * 2001-07-12 2005-04-19 Arrowsmith Technologies Llp Super humanized antibodies
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
GB0410627D0 (en) * 2004-05-12 2004-06-16 Scancell Ltd Specific binding members
CN101189265B (zh) * 2005-06-01 2012-07-04 米克罗麦特股份公司 抗il2抗体
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies

Also Published As

Publication number Publication date
KR20110129935A (ko) 2011-12-02
WO2010105290A1 (en) 2010-09-23
IL214840A (en) 2015-11-30
CA2769276A1 (en) 2010-09-23
IL214840A0 (en) 2011-11-30
JP5746134B2 (ja) 2015-07-08
EA201171133A1 (ru) 2012-03-30
MA33194B1 (fr) 2012-04-02
AU2010225448B2 (en) 2013-10-24
UA108349C2 (uk) 2015-04-27
AU2010225448A1 (en) 2011-09-08
EP2433967A3 (en) 2013-05-01
EA024695B1 (ru) 2016-10-31
US20100297134A1 (en) 2010-11-25
JP2012520329A (ja) 2012-09-06
SG173577A1 (en) 2011-09-29
NZ600915A (en) 2013-09-27
CN102395604A (zh) 2012-03-28
CN102395604B (zh) 2015-11-25
EP2433967A2 (en) 2012-03-28
TN2011000417A1 (en) 2013-03-27
US8470320B2 (en) 2013-06-25
US8901279B2 (en) 2014-12-02
ZA201105875B (en) 2012-11-28
BRPI1009460A2 (pt) 2016-03-01
EP2408820A1 (en) 2012-01-25
US20130280246A1 (en) 2013-10-24
NZ594668A (en) 2012-10-26
EP2408820A4 (en) 2013-01-23

Similar Documents

Publication Publication Date Title
MX2011009704A (es) Anticuerpos humanizados con actividad anti-tumor.
UA114879C2 (uk) Антитіло до cd38 для лікування раку
NZ596490A (en) Monoclonal antibodies that bind GT468 for the treatment of cancer
MX2011009312A (es) Formulaciones de anticuerpos humanizados anti-cd19.
CY1119324T1 (el) Αντισωματα εναντιον csf-1r
IL202092A0 (en) Humanized and chimeric anti-trop-2 antibodies that mediate cancer cell cytotoxicity
CU20130130A7 (es) Anticuerpos tipo receptor de células t específicos para un péptido wt1 presentado por hla-a2
ZA200908344B (en) Chimeric and humanized anti-CD44 antibodies that mediate cancer cell cytotoxicity
UA106890C2 (uk) Гуманізоване антитіло до cdcp1
WO2014011988A3 (en) Enhancing activity of car t cells by co-introducing a bispecific antibody
MX2009002414A (es) Anticuerpos anti-cd19 humanizados y su uso en el tratamiento de oncologia, transplante y enfermedad autoinmunitaria.
MX347078B (es) Uso de celulas t modificadas por receptor de antigeno quimerico para tratar cancer.
NZ603455A (en) Anti-human trop-2 antibody having antitumor activity in vivo
FI3795592T3 (fi) Vasta-aineiden, jotka sitovat lymfosyyttejä aktivoivaa geeni-3:a (lag-3), optimointi ja niiden käytöt
MX2012011768A (es) Anticuerpos que se unen a cd27 humano y uso de los mismos.
NZ593147A (en) Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide
IL213975A0 (en) Treatment of cancer with a humanized anti-egfr igg1 antibody and inriotecan
AR071304A1 (es) Anticuerpos anti cd151 (proteina de membrana de la flia. de las tetraspaninas) utiles para el tratamiento de cancer
CR20120429A (es) Métodos para el tratamiento contra carcinoma escamocelular de cabeza y cuello
SG10201506625VA (en) Monoclonal antibodies for treatment of cancer
WO2011133819A3 (en) Methods of enhancing antibody-dependent cellular cytotoxicity
IL202087A0 (en) Humanized and chimeric anti-cd59 antibodies that mediate cancer cell cytotoxicity
AR078572A1 (es) Anticuerpos quimericos anti-cd151 y sus usos para el tratamiento del cancer
PE20091902A1 (es) Anticuerpos modificadores de enfermedades cancerosas
PE20091365A1 (es) Anticuerpos modificadores de enfermedades cancerosas

Legal Events

Date Code Title Description
FG Grant or registration